Molecular Partners Ag (MOLN) Income towards Parent Company (2020 - 2026)

Molecular Partners Ag (MOLN) posted quarterly Income towards Parent Company of -$16792.1 for Q1 2026, up 10.0% year-on-year from -$15266.2 in Q1 2025, and up 99.98% on a QoQ basis from -$81.8 million in Q4 2025.

Molecular Partners Ag (MOLN) Income towards Parent Company (2020 - 2026) Analysis & Trends

Molecular Partners Ag (MOLN) has reported Income towards Parent Company for 7 consecutive years, with -$16792.1 the latest figure, recorded in Q1 2026.

  • Quarterly Income towards Parent Company rose 10.0% year-over-year to -$16792.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.9 million (down 31.54% YoY) and the FY2025 annual result came in at $100.5 million, down 37.84% from the prior year.
  • Income towards Parent Company advanced to -$16792.1 in Q1 2026 per MOLN's latest filing, from -$81.8 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for MOLN reached as high as $127.7 million in Q4 2022 and fell as low as -$81.8 million in Q4 2025.
  • A 5-year average of -$6.5 million and a median of -$16792.1 in 2026 frame the typical range for Income towards Parent Company.
  • Annual changes were most pronounced in 2022 — Income towards Parent Company jumped 1005.54% — and 2023, when it tumbled 278.7%.
  • Year by year, Income towards Parent Company stood at $127.7 million in 2022, then plunged by 156.44% to -$72.1 million in 2023, then grew by 13.69% to -$62.2 million in 2024, then sank by 31.56% to -$81.8 million in 2025, then surged by 99.98% to -$16792.1 in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$16792.1, -$81.8 million, and -$14803.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Molecular Partners Ag 147.97 Mn 147.97 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -16,792.10
Dec 31, 2025 -81.84 Mn
Sep 30, 2025 -14,803.30
Jun 30, 2025 -24,645.31
Mar 31, 2025 -18,656.89
Dec 31, 2024 -62.21 Mn
Sep 30, 2024 -18,940.19
Jun 30, 2024 -16,677.58
Mar 31, 2024 -12,981.38
Dec 31, 2023 -72.07 Mn
Sep 30, 2023 -12,957.15
Jun 30, 2023 -17.78 Mn
Mar 31, 2023 -15,983.58
Dec 31, 2022 127.71 Mn
Sep 30, 2022 -13,800.36
Jun 30, 2022 -4.70 Mn
Mar 31, 2022 165,800.92
Dec 31, 2021 -69.13 Mn
Sep 30, 2021 -13,411.64
Jun 30, 2021 -36.79 Mn